LRIG1 is a triple threat: ERBB negative regulator, intestinal stem cell marker and tumour suppressor

British Journal of Cancer

Volumn 108, Issue 9, 2013, Pages 1765-1770

  Wang, Y ^a   Poulin, E J ^b   Coffey, R J ^a,c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

EGFR signalling; LRIG1; Stem cell; Tumour suppressor

Indexed keywords

CELL MARKER; CELL SURFACE PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; LRIG1 PROTEIN; MEMBRANE PROTEIN; UNCLASSIFIED DRUG;

BREAST CANCER; CARCINOGENESIS; COLORECTAL CANCER; DEGRADATION; GLIOBLASTOMA; HETEROLOGOUS EXPRESSION; HUMAN; HYPOPHYSIS ADENOMA; INTESTINE CELL; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHATIC LEUKEMIA; MELANOMA; MENINGIOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REVIEW; SQUAMOUS CELL CARCINOMA; STEM CELL; TUMOR SUPPRESSOR GENE; UBIQUITINATION; UTERINE CERVIX CANCER;

ADENOMA; ANIMALS; BIOLOGICAL MARKERS; GENES, TUMOR SUPPRESSOR; HUMANS; INTESTINES; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MICE; NEOPLASMS; ONCOGENE PROTEINS V-ERBB; RECEPTOR, EPIDERMAL GROWTH FACTOR; STEM CELLS; TUMOR SUPPRESSOR PROTEINS;

EID: 84878598705     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.138     Document Type: Review

References (41)

1. Abraira VE, Del Rio T, Tucker AF, Slonimsky J, Keirnes HL, Goodrich LV (2008) Cross-repressive interactions between Lrig3 and netrin 1 shape the architecture of the inner ear. Development 135: 4091-4099.
2. Abraira VE, Satoh T, Fekete DM, Goodrich LV (2010) Vertebrate Lrig3-ErbB interactions occur in vitro but are unlikely to play a role in Lrig3- dependent inner ear morphogenesis. PLoS One 5: e8981.
3. Cai M, Han L, Chen R, Ye F, Wang B, Han F, Lei T, Guo D (2009) Inhibition of LRIG3 gene expression via RNA interference modulates the proliferation, cell cycle, cell apoptosis, adhesion and invasion of glioblastoma cell (GL15). Cancer Lett 278: 104-112.
4. Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ (1998) The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature 396: 177-180.
5. Ghasimi S, Haapasalo H, Eray M, Korhonen K, Brannstrom T, Hedman H, Andersson U (2012) Immunohistochemical analysis of LRIG proteins in meningiomas: correlation between estrogen receptor status and LRIG expression. J Neurooncol 108: 435-441.
6. Goldoni S, Iozzo RA, Kay P, Campbell S, McQuillan A, Agnew C, Zhu JX, Keene DR, Reed CC, Iozzo RV (2007) A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activity. Oncogene 26: 368-381.
7. Gur G, Rubin C, Katz M, Amit I, Citri A, Nilsson J, Amariglio N, Henriksson R, Rechavi G, Hedman H, Wides R, Yarden Y (2004) LRIG1 restricts growth factor signalling by enhancing receptor ubiquitylation and degradation. Embo J 23: 3270-3281.
8. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
9. Hanlon K, Rudin CE, Harries LW (2009) Investigating the targets of MIR-15a and MIR-16-1 in patients with chronic lymphocytic leukaemia (CLL). PLoS One 4: e7169.
10. Hedman H, Lindstrom AK, Tot T, Stendahl U, Henriksson R, Hellberg D (2010) LRIG2 in contrast to LRIG1 predicts poor survival in early-stage squamous cell carcinoma of the uterine cervix. Acta Oncol 49: 812-815.
11. Hedman H, Nilsson J, Guo D, Henriksson R (2002) Is LRIG1 a tumour suppressor gene at chromosome 3p14.3? Acta Oncol 41: 352-354.
12. Hellberg D, Tot T, Stendahl U (2009) Pitfalls in immunohistochemical validation of tumour marker expression-exemplified in invasive cancer of the uterine cervix. Gynecol Oncol 112: 235-240.
13. Holmlund C, Haapasalo H, Yi W, Raheem O, Brannstrom T, Bragge H, Henriksson R, Hedman H (2009) Cytoplasmic LRIG2 expression is associated with poor oligodendroglioma patient survival. Neuropathology 29: 242-247.
14. Jensen KB, Collins CA, Nascimento E, Tan DW, Frye M, Itami S, Watt FM (2009) Lrig1 expression defines a distinct multipotent stem cell population in mammalian epidermis. Cell Stem Cell 4: 427-439.
15. Johansson M, Oudin A, Tiemann K, Bernard A, Keunen O, Fack F, Golebiewska A, Stieber D, Wang B, Hedman H, Niclou SP (2013) The soluble form of the tumor suppressor Lrig1 potently inhibits in vivo glioma growth irrespective of EGF receptor status. Neuro-Oncology. doi:10.1093/neuonc/not054.
16. Krig SR, Frietze S, Simion C, Miller JK, Fry WH, Rafidi H, Kotelawala L, Qi L, Griffith OL, Gray JW, Carraway 3rd KL, Sweeney C (2011) Lrig1 is an estrogen-regulated growth suppressor and correlates with longer relapsefree survival in ERalpha-positive breast cancer. Mol Cancer Res 9: 1406-1417.
17. Laederich MB, Funes-Duran M, Yen L, Ingalla E, Wu X, Carraway 3rd KL, Sweeney C (2004) The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases. J Biol Chem 279: 47050-47056.
18. Ledda F, Bieraugel O, Fard SS, Vilar M, Paratcha G (2008) Lrig1 is an endogenous inhibitor of Ret receptor tyrosine kinase activation, downstream signalling, and biological responses to GDNF. J Neurosci 28: 39-49.
19. Lee JM, Kim B, Lee SB, Jeong Y, Oh YM, Song YJ, Jung S, Choi J, Lee S, Cheong KH, Kim DU, Park HW, Han YK, Kim GW, Choi H, Song PH, Kim KA (2012) Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody. Oncogene; e-pub ahead of print 3 December 2012; doi:10.1038/onc.2012.551.
20. Lindstrom AK, Ekman K, Stendahl U, Tot T, Henriksson R, Hedman H, Hellberg D (2008) LRIG1 and squamous epithelial uterine cervical cancer: correlation to prognosis, other tumour markers, sex steroid hormones, and smoking. Int J Gynecol Cancer 18: 312-317.
21. Ljuslinder I, Golovleva I, Palmqvist R, Oberg A, Stenling R, Jonsson Y, Hedman H, Henriksson R, Malmer B (2007) LRIG1 expression in colorectal cancer. Acta Oncol 46: 1118-1122.
22. Maitra A, Wistuba II, Washington C, Virmani AK, Ashfaq R, Milchgrub S, Gazdar AF, Minna JD (2001) High-resolution chromosome 3p allelotyping of breast carcinomas and precursor lesions demonstrates frequent loss of heterozygosity and a discontinuous pattern of allele loss. Am J Pathol 159: 119-130.
23. Mao F, Wang B, Xi G, Sun W, Zhang H, Ye F, Guo D, Lei T (2012) Effects of RNAi-mediated gene silencing of LRIG1 on proliferation and invasion of glioma cells. J Huazhong Univ Sci Technolog Med Sci 32: 227-232.
24. Miller JK, Shattuck DL, Ingalla EQ, Yen L, Borowsky AD, Young LJ, Cardiff RD, Carraway 3rd KL, Sweeney C (2008) Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer. Cancer Res 68: 8286-8294.
25. Ostroff RM, Bigbee WL, Franklin W, Gold L, Mehan M, Miller YE, Pass HI, Rom WN, Siegfried JM, Stewart A, Walker JJ, Weissfeld JL, Williams S, Zichi D, Brody EN (2010) Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer. PLoS One 5: e15003.
26. Powell AE, Wang Y, Li Y, Poulin EJ, Means AL, Washington MK, Higginbotham JN, Juchheim A, Prasad N, Levy SE, Guo Y, Shyr Y, Aronow BJ, Haigis KM, Franklin JL, Coffey RJ (2012) The pan-ErbB negative regulator Lrig1 is an intestinal stem cell marker that functions as a tumor suppressor. Cell 149: 146-158.
27. Rouam S, Moreau T, Broet P (2010) Identifying common prognostic factors in genomic cancer studies: a novel index for censored outcomes. BMC Bioinformat 11: 150.
28. Scacheri PC, Crabtree JS, Novotny EA, Garrett-Beal L, Chen A, Edgemon KA, Marx SJ, Spiegel AM, Chandrasekharappa SC, Collins FS (2001) Bidirectional transcriptional activity of PGK-neomycin and unexpected embryonic lethality in heterozygote chimeric knockout mice. Genesis 30: 259-263.
29. Shattuck DL, Miller JK, Laederich M, Funes M, Petersen H, Carraway 3rd KL, Sweeney C (2007) LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy. Mol Cell Biol 27: 1934-1946.
30. Sheu JJ, Lee CH, Ko JY, Tsao GS, Wu CC, Fang CY, Tsai FJ, Hua CH, Chen CL, Chen JY (2009) Chromosome 3p12.3-p14.2 and 3q26.2-q26.32 are genomic markers for prognosis of advanced nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 18: 2709-2716.
31. Stutz MA, Shattuck DL, Laederich MB, Carraway 3rd KL, Sweeney C (2008) LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII. Oncogene 27: 5741-5752.
32. Suzuki Y, Miura H, Tanemura A, Kobayashi K, Kondoh G, Sano S, Ozawa K, Inui S, Nakata A, Takagi T, Tohyama M, Yoshikawa K, Itami S (2002) Targeted disruption of LIG-1 gene results in psoriasiform epidermal hyperplasia. FEBS Lett 521: 67-71.
33. Suzuki Y, Sato N, Tohyama M, Wanaka A, Takagi T (1996) cDNA cloning of a novel membrane glycoprotein that is expressed specifically in glial cells in the mouse brain. LIG-1, a protein with leucine-rich repeats and immunoglobulin-like domains. J Biol Chem 271: 22522-22527.
34. Tanemura A, Nagasawa T, Inui S, Itami S (2005) LRIG-1 provides a novel prognostic predictor in squamous cell carcinoma of the skin: immunohistochemical analysis for 38 cases. Dermatol Surg 31: 423-430.
35. Thomasson M, Hedman H, Ljungberg B, Henriksson R (2012) Gene expression pattern of the epidermal growth factor receptor family and LRIG1 in renal cell carcinoma. BMC Res Notes 5: 216.
36. Thomasson M, Wang B, Hammarsten P, Dahlman A, Persson JL, Josefsson A, Stattin P, Granfors T, Egevad L, Henriksson R, Bergh A, Hedman H (2010) LRIG1 and the liar paradox in prostate cancer: a study of the expression and clinical significance of LRIG1 in prostate cancer. Int J Cancer 128: 2843-2852.
37. Willers CP, Siebert R, BardenheuerW, Lux A,Michaelis S, Seeber S, Luboldt HJ, Opalka B, Schutte J (1996) Genetic instability of 3p12-p21-specific microsatellite sequences in renal cell carcinoma. Br J Urol 77: 524-529.
38. Wong VW, Stange DE, Page ME, Buczacki S, Wabik A, Itami S, van de Wetering M, Poulsom R, Wright NA, Trotter MW, Watt FM, Winton DJ, Clevers H, Jensen KB (2012) Lrig1 controls intestinal stem-cell homeostasis by negative regulation of ErbB signalling. Nat Cell Biol 14: 401-408.
39. Yi W, Holmlund C, Nilsson J, Inui S, Lei T, Itami S, Henriksson R, Hedman H (2010) Paracrine regulation of growth factor signalling by shed leucine-rich repeats and immunoglobulin-like domains 1. Exp Cell Res 317: 504-512.
40. Zhang H, Yan Q, Xu S, Ou Y, Ye F, Wang B, Lei T, Guo D (2011) Association of expression of Leucine-rich repeats and immunoglobulin-like domains 2 gene with invasiveness of pituitary adenoma. J Huazhong Univ Sci Technolog Med Sci 31: 520-523.
41. Zhao H, Tanegashima K, Ro H, Dawid IB (2008) Lrig3 regulates neural crest formation in Xenopus by modulating Fgf and Wnt signaling pathways. Development 135: 1283-1293.